Literature DB >> 2084231

Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis--lessons from Hodgkin's disease and coronary artery disease.

T Pincus, L F Callahan.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2084231

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  8 in total

1.  Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies.

Authors:  Paul Hasler; Cem Gabay
Journal:  Semin Immunopathol       Date:  2017-06-21       Impact factor: 9.623

2.  Utility of disease modifying antirheumatic drugs in "sawtooth" strategy. A prospective study of early rheumatoid arthritis patients up to 15 years.

Authors:  T Sokka; P Hannonen
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

3.  Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients?

Authors:  N Maiden; H A Capell; R Madhok; R Hampson; E A Thomson
Journal:  Ann Rheum Dis       Date:  1999-09       Impact factor: 19.103

4.  Inhibiting interleukin-6 in rheumatoid arthritis.

Authors:  Ernest Choy
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

5.  Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis--results of a double-blind multicentre study.

Authors:  K Krüger; M Schattenkirchner
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

Review 6.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

7.  Prevalence of metacarpal osteopenia in young rheumatoid arthritis patients.

Authors:  A A Kalla; O L Meyers; R Laubscher
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

8.  Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.

Authors:  Takao Koike; Masayoshi Harigai; Shigeko Inokuma; Naoki Ishiguro; Junnosuke Ryu; Tsutomu Takeuchi; Yoshiya Tanaka; Hisashi Yamanaka; Koichi Fujii; Takunari Yoshinaga; Bruce Freundlich; Michio Suzukawa
Journal:  Rheumatol Int       Date:  2011-02-16       Impact factor: 2.631
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.